Discontinuation of statin therapy
Pro Research Analysisby 
Searched over 200M research papers
Statin Therapy Discontinuation: Prevalence and Patient Characteristics
Discontinuation of statin therapy is common, with studies showing that 41–47% of patients stop taking statins within a few years of starting, whether for primary or secondary prevention of cardiovascular disease 24. Many of these patients, however, eventually restart therapy, with 72–75% resuming statin use after discontinuation . Discontinuation is more likely among younger patients (≤50 years), older adults (≥75 years), women, and those with chronic liver disease 29. Additionally, patients from ethnic minority groups, current smokers, and those with type 1 diabetes are more likely to discontinue but also more likely to restart, while those with hypertension or type 2 diabetes are less likely to discontinue .
Reasons for Statin Discontinuation: Patient-Reported Insights
The most frequently reported reason for discontinuing statin therapy is the experience or fear of adverse events, particularly musculoskeletal and connective tissue disorders 310. Patient concerns about side effects, whether experienced or anticipated, are the leading cause of both refusal and discontinuation of statins 310. Many patients who discontinue statins are willing to reconsider therapy if offered again, indicating that discontinuation may often be related to temporary concerns or poor communication rather than a permanent decision .
Clinical Outcomes and Risks Associated with Statin Discontinuation
Discontinuing statin therapy is associated with increased risks of adverse cardiovascular outcomes, including higher rates of myocardial infarction, cardiovascular death, and all-cause mortality, especially in patients with a history of cardiovascular events such as ischemic stroke 1478. For example, patients who discontinued statins after an ischemic stroke had a significantly higher risk of death within one year compared to those who continued therapy . These findings highlight the importance of maintaining statin therapy in most patient populations to reduce cardiovascular risk 1478.
Special Populations: Older Adults and Advanced Illness
Guidelines suggest that the benefits of statin therapy may be limited in certain populations, such as patients with advanced, life-limiting illness, those on dialysis, or older adults over 75 years without atherosclerotic cardiovascular disease 156. In patients with limited life expectancy, discontinuing statins has been shown to be safe, with no significant difference in short-term mortality or cardiovascular events, and may even improve quality of life and reduce medication costs . For older adults, recommendations for discontinuation are nuanced and should be individualized based on health status and life expectancy .
Statin Discontinuation and Myopathy
Discontinuation of statins is also linked to an increased risk of statin-induced myopathy, with women and older adults at higher risk for both discontinuation and myopathy . This relationship underscores the need for careful monitoring and patient education regarding potential side effects and the importance of adherence .
Conclusion
Statin discontinuation is common and often driven by concerns about side effects, but many patients are open to restarting therapy. Discontinuation is associated with increased cardiovascular risk in most populations, except in those with advanced illness or limited life expectancy, where stopping statins may be appropriate and beneficial. Patient-provider communication and individualized care are essential to optimize statin use and improve outcomes 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic